Incidence and outcome of mucormycosis in diabetic patients with COVID-19

https://doi.org/10.53730/ijhs.v6nS5.11480

Authors

  • Melvindominic Assistant professor, Department of Emergency Medicine, Vinayaka Mission's KirupanandaVariyar Medical College & Hospital
  • M Senthil Associate Professor, Department of Emergency Medicine, Vinayaka Mission's Kirupananda Variyar Medical College & Hospital
  • C. Hari Hara Sudhan Assistant professor, Department of Emergency Medicine, Vinayaka Mission's Kirupananda Variyar Medical College & Hospital
  • Syed Abthahir S Junior Resident (Post Graduate), Department of Emergency Medicine, Vinayaka Mission's Kirupananda Variyar Medical College & Hospital
  • Chanjal KS Junior Resident (Post Graduate), Department of Emergency Medicine, Vinayaka Mission's Kirupananda Variyar Medical College & Hospital

Abstract

Aims and objectives: Diabetes Mellitus predisposes patients to invasive fungal infections. Aim of this study is to find out the incidence and outcome of Mucormycosis in diabetic patients with COVID-19. Materials and Methodology: A Retrospective study of 150 patients with COVID-19 who were admitted in VMKVMCH COVID-19 Ward, Salem from May 2021 to July 2021 was included in the study. Results: Among 150 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive. Conclusion: Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.

Downloads

Download data is not yet available.

Published

02-08-2022

How to Cite

Melvindominic, M., Senthil, M., Sudhan, C. H. H., Syed, A. S., & Chanjal, K. S. (2022). Incidence and outcome of mucormycosis in diabetic patients with COVID-19. International Journal of Health Sciences, 6(S5). https://doi.org/10.53730/ijhs.v6nS5.11480

Issue

Special Issue V

Section

Peer Review Articles
Copyright & Licensing

Copyright (c) 2022 International journal of health sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.